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ABSTRACT
Background:
Pulmonary embolism (PE) is the most common cause of preventable deaths in 
hospitalized patients.
Objectives:
To determine the incidence and associated features of PE at Chris Hani Baragwanath 
Academic Hospital (CHBAH) over one year.
Methods:
A retrospective study was performed of patients with confirmed PE on computed 
tomography of the pulmonary arteries (CTPA) during 2013 and by means of a formatted 
data collection sheet, demographical and other relevant data was collected.
Results:
There were 498 CTPAs requested at CHBAH in 2013 and 147 (30%) of these confirmed 
the presence of PE. The mean age of the patients with PE was 47 ± 15.49 years. At least 
41 % of the patients with PE were HIV positive. The Wells and revised Geneva score were 
comparable in predicting clinical probability of PE. Only 15% of the patients with high risk 
PE were thrombolysed, with no documented complications.
Conclusion:
PE is a common and serious medical condition in CHBAH and its management needs 
further optimization to improve clinical outcomes.
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Chapter 1: PROTOCOL WITH EXTENDED LITERATURE REVIEW
1.1 Introduction
Pulmonary embolism (PE) occurs when there is an occlusion to the blood supply to a 
portion of the lung caused by a blood clot which embolises to lungs from peripheral veins. 
This prevents oxygenated blood from reaching the brain and other vital organs.1
The European Society of Cardiology (ESC) guidelines have proposed classifying PE 
according to the estimated risk of early death (inpatient or 30 day mortality) directly related 
to the PE. With this classification a high risk PE is characterized by haemodynamic 
instability, which according to the ESC guidelines is defined as a systolic blood pressure 
(SBP) of less than 90 or a drop in blood pressure of > 40mmHg for more than 15 minutes 
that cannot be explained by another cause such as new onset arrhythmia, hypovolaemia 
or sepsis.2,3 High risk PE may or may not be accompanied by right ventricular (RV)
o
dysfunction and myocardial injury, it carries a short term mortality of 15%.
Non-high risk PE is divided into moderate risk and low risk PE. Moderate risk PE is 
diagnosed when there is RV dysfunction and/or myocardial injury in a haemodynamically 
stable patient and low risk PE is when there is neither RV dysfunction nor myocardial 
injury.2 In the more recent ESC guidelines from 2014 the subdivision of non-high risk PE 
into moderate and low risk PE is not mentioned, most likely to not complicate the clinically 
relevant distinction between high and non-high risk PE.3
1.2 Epidemiology
The annual incidence of PE in South Africa is unknown but in the United States of America 
(USA) it is estimated at 600 000 cases.2'4 The prevalence amongst hospitalized patients 
over a 21 year period (1979 -1999) in the USA was 0.4%.2,5 Mortality figures for acute PE
l
range from 7 — 11 % ,2 In Sweden, an analysis of 2356 autopsies performed in 1987, 
showed venous thromboembolism (VTE) in 595 (25%) and PE in 431 (18.3%). In 308 of 
the autopsies, PE was considered to have caused or contributed to the deaths.26 PE is 
regarded as the most common cause of preventable deaths in hospitalized patients and in 
its chronic phase is also a cause of great morbidity.3 The annual healthcare cost 
attributable to treatment of VTE is estimated to be more than 1.5 billion US dollars.7 These 
studies leave no doubt that PE is a prevalent condition, and is associated with a high 
mortality rate.
In a study from the USA conducted in 2009, reviewing the trends of PE it was found that 
the majority of the patients with PE were nonsurgical (71.2%), this may be attributable to 
various studies finding discrepancies in the use of VTE prophylaxis between surgical and 
non-surgical patients.7
1.3 Thrombolysis
According to the ESC and American College of Chest Physicians (ACCP) guidelines, 
thrombolytic therapy is indicated in high risk PE, even up to 14 days after the onset of 
symptoms, unless there are contra-indications present (Table 1).
In cases where there are contra-indications present to thrombolysis or where thrombolysis 
has failed, surgical or percutaneous catheter embolectomy should be performed where 
feasible.2,3
The first report of thrombolysis (streptokinase) being used in PE was published in 19648, 
and the first randomized controlled trial, the urokinase PE trial showed better acute 
response with thrombolytic therapy than with anti-coagulants alone.9 In the urokinase PE
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trial published in 1970 urokinase was proven to be superior when compared to heparin in 
achieving resolution of pulmonary emboli at 24hrs, as assessed by angiography and 
perfusion scans.9 Another study by Sharma et al looked at pulmonary capillary perfusion 
and diffusion as endpoints after treatment for PE and found a significantly greater 
improvement in both these parameters when thrombolytics were used.10 Follow -  up of 
these patients at an average of seven years after therapy, showed lower pulmonary 
arterial pressures and pulmonary vascular resistance in the thrombolytic group compared 
to the group that received anticoagulation alone, demonstrating a long term benefit of 
thrombolysis.11 In a randomized controlled trial by Goldhaber et al in 1993 which included 
101 patients treated with either a thrombolytic or heparin assessed the echocardiographic 
changes in right ventricular function and the change in pulmonary perfusion in these two 
groups. Patients who received a thrombolytic showed increased improvement in right 
ventricular function and pulmonary perfusion than those who only received heparin. 12 All 
these studies demonstrate an improvement in haemodynamics with the use of 
thrombolytics than with heparin alone and therefore haemodynamically unstable patients 
as specified in the ESC guidelines should be treated with thrombolysis.
Use of thrombolysis for non-high risk PE with haemodynamic stability and features of right 
ventricular (RV) enlargement or hypokinesia or the elevation of biomarkers of RV injury 
was explored in the Moderate Pulmonary Embolism Treated with Thrombolysis (MOPETT 
trial) where low dose thrombolysis for “moderate” PE was used and the pulmonary arterial 
systolic pressures (PASP) assessed at 28 months after thrombolysis.13 The investigators 
found a significant decrease in the PASP at approximately 28 months in patients with non- 
high risk PE with features of RV strain treated with a low dose thrombolytic agent. 13
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A large observational study of unstable patients with acute PE (n = 72,230) found that 
thrombolytic therapy was associated with lower all-cause mortality (15 versus 47 percent), 
as well as lower mortality attributable to PE (8.4 versus 42 percent).14 The same study 
highlighted that thrombolysis was underutilized (only used in 30% of unstable patients) and 
less likely to be administered in older patients (> 60yr) and in patients with co-morbid 
conditions.14 Only 16% of the unstable patients diagnosed with PE died on the day of 
admission and did not receive thrombolytic therapy, despite having enough time to do so.14 
This brings to light an area of clinician uncertainty and lack of confidence in the indication 
for thrombolysis. In a follow up study performed by the same group, it was found that 
unstable patients who received thrombolytic therapy regardless of age and co-morbidities, 
had a lower in hospital mortality rate.15
According to the ESC guidelines percutaneous catheter embolectomy is indicated when 
there are absolute contraindications to thrombolysis or in cases where thrombolysis has 
failed. It may also be considered as an alternative to surgery in high risk PE patients in 
centers where cardiopulmonary bypass facilities are not available.2,3
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Table 1: Adopted from the ESC guidelines 2014
Contraindications to fibrinolytic therapy _____
Absolute contraindications ____ _______
Haemorrhagic stroke or stroke of unknown origin at any time______
Ischaemic stroke in preceding 6 months_______________________
Central nervous system damage or neoplasms_________________
Recent major trauma/surgery/head injury (within preceding 3 weeks)
Gastrointestinal bleeding within the last month______ ___________
Known bleeding risk______________________________________
Relative contraindications_________________ ______________
Transient ischaemic attack in preceding 6 months_______________
Oral anticoagulant therapy_________________________________
Pregnancy or within 1 week post-partum______________________
Non-compressible puncture site_____________________________
Traumatic resuscitation____________________________________
Refractory hypertension (systolic blood pressure > 180mmHg)_____
Advanced liver disease____________________________________
Infective Endocarditis______________________________________
Active peptic ulcer________________________________________
1.4 Serum D-dimer
D-dimer is a degradation product of cross linked fibrin and can be detected in serum 
through various assays, and its sensitivity and specificity for the diagnosis of pulmonary 
embolism has been studied extensively.16 The Enzyme-Linked ImmunoSorbant Assay 
(ELISA) and quantitative rapid ELISA carry a sensitivity of 95% to 100% but the specificity 
is better with the rapid whole-blood test (73.3% versus 67.9%). The positive predictive 
value was poor for both tests. Various conditions, (recent surgery, infection, malignancy, 
pregnancy and puerperium, renal dysfunction, cigarette smoking, and old age) cause 
raised D-dimer levels.16
A negative D-dimer test reasonably excludes acute VTE , especially in patients with a low 
or intermediate clinical probability and is comparable to a lung scan in low clinical 
probability patients.16 The sensitivity of D-dimer also decreases from the onset of 
symptoms with a drop of 25 % from the initial value after 1-2 weeks.16 One study 
concluded that acute VTE could not be excluded if the D-dimer was done 1 week after
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onset of symptoms.16 D-dimer levels are also affected by anti-coagulation and levels 
decreased by 25% over 24 hours with a resultant decrease in sensitivity.16 Elaboration on 
the usefulness of D-dimer levels in special circumstances is mentioned below.
1.4.1 Malignancy
D-dimer testing has the highest sensitivity and negative predictive value in oncology 
patients to exclude a VTE , although the validity of the test is not too reliable due to high 
levels even in the absence of thrombosis.16 D-dimer levels > 8mg/l are more associated 
with the presence of a malignancy. The following risk factors increase the likelihood of 
VTE in oncology, location of the primary tumour, stage and initial period after diagnosis of 
tumour and associated comorbidities.16
1.4.2 Pregnancy
Pregnancy is a prothrombotic state and the risk of VTE is raised in the postpartum period 
with an incidence of 1 in 1000 pregnancies.2,316 Normal D-dimer levels vary in pregnant 
patients depending on the gestation.16 At cut off values for the first, second and third 
trimester of 0.286mg/l, 0.457mg/l and 0.644mg/l respectively, serum D-dimer testing has a 
100% sensitivity.16
1.4.3 Renal failure
In renal failure patients the serum D-dimer test is of limited value as it represents 
increased fibrin turnover as well as decreased elimination.16 The risk of VTE in patients 
with renal dysfunction increases as the glomerular filtration rate reaches 75ml/min/1,73m2 
with the relative risk of 2.1 as this stage approaches.16
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1.4.4 The elderly population
The role of D-dimer testing after the age of 80 years is limited.216 The specificity of D- 
dimer levels is dramatically reduced to 10% in patients above 80 years of age.3 In one 
meta-analysis where age adjusted cut offs were used (age x 10pg/l above 50 years) , the 
specificity of D-dimer levels increased by 34-36% while the sensitivity stayed >97%.3,17 
This would also allow a reduction in the number of false positive results.
The level of D-dimer has been shown to correlate with the likelihood of VTE, with the 
specificity being 93% with levels > 4mg/l.16Thus, a higher D-dimer level should instigate a 
more aggressive diagnostic approach.
1.5 The Wells and revised Geneva scores
The Wells score is a predictor of probability of PE and is based on six objective and one 
subjective clinical judgment.2,18 It has been validated in 2 schemes, the 3 category scheme 
and the 2 category scheme (Table 2).2,18 The three category scheme divides the score in 
low, intermediate and high probability categories and the two category scheme is divided 
into PE likely and PE unlikely categories.218 A more simplified version of the original Wells 
score which assign only one point per variable was derived in 2008 by Gibson NS et al 
and validated as being comparable and just as clinically useful as the original Wells 
score.3,19
The revised Geneva score although less commonly used is based on all objective criteria 
(Table 2).2,20 Both scores have however yielded similar results.2 As with the Wells score a 
simpler version of the revised Geneva score has been validated which also only assigns 
one point per variable to lead to easier calculation of the score and improve clinical 
utilization.321
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Table 2: Clinical predictor rules for PE adapted from ESC guidelines 2014
Items Clinical decisions rule points
Wells rule OriginalVersion
Simplified
version
Previous PE or DVT 1.5 1
Heart rate > 100 b.p.m 1.5 1
Surgery or immobilization within the past four weeks 1.5 1
Haemoptysis 1 1
Active cancer 1 1
Clinical signs of DVT 3 1
Alternative diagnosis less likely than PE 3 1
Clinical probability
Three-level score
Low 0-1 N/A
Intermediate 2-6 N/A
High >7 N/A
Two-level score
PE unlikely 0-4 0-1
PE likely >5 >2
Revised Geneva score OriginalVersion
Simplified
version
Previous PE or DVT 3 1
Heart rate
75-94 b.p.m 3 1
>95b.p.m 5 2
Surgery or fracture within the past month 2 1
Haemoptysis 2 1
Active cancer 2 1
Unilateral lower limb pain 3 1
Pain on lower limb deep venous palpation and unilateral 
oedema 4 1
Age > 65 years 1 1
Clinical probability
Three-level score
Low 0-3 0-1
Intermediate 4-10 2-4
High >11 >5
Two-level score
PE unlikely 0-5 0-2
PE likely >6 >3
N/A -  not applicable; b.p.m beats per minute
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1.6 Human immunodeficiency virus and venous thrombo-embolism
Evidence shows that patients with human immunodeficiency virus (HIV) have multiple risk 
factors and a 2-10 fold increased risk of venous thrombo-embolism (VTE) compared to the 
general population.22,23,24 In patients with HIV infection, the rate of VTE is increased in 
patients < 50 years of age as compared to controls and also those who have a CD4 count 
< 200 cells/mm3.22 2324 The increased incidence of VTE at a younger age is partially 
explained by the so called “premature aging” which occurs in HIV positive individuals 
through defects in the immune system which are more commonly seen at CD4 counts < 
200 cells/mm3. These defects include a low CD4:CD8 ratio, low naive : memory cell ratio 
and abnormal T cell function.25
HIV infection is a prothrombotic state through various risk factors related to the host, the 
virus itself and anti-retrovirals.25 Host factors include age, intravenous drug use (15 times 
increased risk of VTE compared to HIV infected patients who did not use intravenous 
drugs) and hypercoagulability.25 The hypercoagulability is attributable to various 
haematological abnormalities such as protein S deficiency and protein C deficiency, 
presence of anticardiolipin and lupus anticoagulant antibodies, increased tissue factor 
expression, increased level of microparticles and homocysteine and lastly abnormal 
endothelial function secondary to HIV itself.25
The viral factors include CD4 counts < 200 cells/mm3, presence of active opportunistic 
infections, (especially cytomegalovirus (CMV) infection, pneumocystis jiroveci pneumonia 
(PJP), mycobacterium tuberculosis and mycobacterium avium intracellulare (MAI) 
infections) and HIV associated malignancies especially Kaposi sarcoma.25 CMV infection, 
particularly with gastrointestinal involvement is associated with VTE and its prevalent with 
comorbid HIV infection is reported at 9.8%. 25 There is an increased occurrence of
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antiphospholipid syndrome in PJP patients with HIV and may explain the increased 
incidence of VTE in these patients.25 MTB induces cytokines through activation of 
macrophages. These cytokines (TNF-a, IL-1 and IL-6) promote coagulopathy by various 
means, such as blocking the protein C pathway and altering new platelet function.25 
Anticardiolipin antibodies are induced by MAI and MTB but a causal relationship with VTE 
in these patients is lacking.25
The third risk factor relates to anti-retrovirals and in particular to protease inhibitors 
(PI).22,25 These drugs are associated with promoting thrombosis through various 
mechanisms. Pis have an effect on metabolism in the liver, especially on the cytochrome 
P450 system and promote a thrombotic state by interfering with regulation of thrombotic 
proteins. They are also associated platelet and endothelial dysfunction and undermining 
the anticoagulant pathways.25
1.7 Complications of thrombolysis
Bleeding is a much feared risk of thrombolytic therapy and has led to reluctance in its use 
despite there being clear indications to thrombolyse patients. In a retrospective study that 
included 312 patients from five previous studies of thrombolysis for PE, intracranial 
haemorrhage occurred in 6 patients (1.9%) and 2 of these were patients where 
thrombolysis was contraindicated due to the presence of pre-existing intracranial disease, 
the frequency of intracranial haemorrhage was 1.9% 26 In the prospective International 
Cooperative Pulmonary Embolism Registry which consisted of 2454 patients, there was 
3% incidence of intracranial haemorrhage in patients who received thrombolysis26
According to the ESC guidelines, thrombolysis is the first line of treatment in patients with 
high risk PE presenting with cardiogenic shock and/or persistent arterial hypotension, with
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very few absolute contra-indications (table 1 ).2 3 This recommendation is shared by the 
ACCP guidelines who advise the use of thrombolytic therapy in patients with acute PE 
associated with hypotension, SBP < 90 mm Hg and who do not have a high bleeding 
risk.26
1.8 Computed tomography of the pulmonary arteries (CTPA)
CTPA is the investigation of choice for imaging of the pulmonary vasculature up to the 
segmental level. 2 The Prospective Investigation On Pulmonary Embolism Diagnosis study 
II series (PIOPED) showed that (multi detector) CTPA carries a sensitivity of 83% and a 
specificity of 96%.2 28 This study also emphasized the importance of clinical evaluation in 
patient’s suspected of having PE and categorizing them according to high, intermediate 
and low risk based on the Wells criteria, as this influences the interpretation of the CTPA 
report. The correlation between a positive CTPA and a high, intermediate or low clinical 
probability of pulmonary embolism based on the Well’s criteria was 96%, 92% and 58% 
respectively .The likelihood that a patient did not have a PE based on a negative CTPA in 
the low, intermediate and high risk groups was 96, 89 and 60 % respectively.2 28 Therefore 
the PIOPED series which included 824 patients and is the largest study of its kind, 
emphasizes the importance of concomitant clinical risk evaluation for accurate 
interpretation of CTPA reports.2
1.9 Study aim and objectives
1.9.1 Aim
No similar studies focusing on the features and management of PE have been conducted 
in South Africa (SA). This study will assess the number of high risk and non-high risk PE 
confirmed on CTPA at CHBAH over the period of one year.
The clinical significance of the various characteristics in patients with confirmed PE will be 
reviewed and the management of PE at CHBAH will be evaluated.
l i
1.9.1 Objectives
1. To determine the incidence of PE (high risk and non-high risk) over the period of 
2013 in CHBAH in cases where a CTPA was ordered.
2. To determine the HIV status and CD4 counts (whether above or below 200) of 
patients with confirmed PE on CTPA.
3. To determine the level of D-dimers in patients with a positive CTPA for PE.
4. To compare the accuracy of the Wells and revised Geneva score in determining the 
probability of PE in patients with positive CTPAs.
5. To determine whether thrombolytic therapy was administered for high risk PE, as 
confirmed on CTPA and to assess the occurrence of complications related to 
thrombolytic therapy.
6. To determine whether surgical or percutaneous catheter embolectomy was used in 
patients with high risk PE where thrombolytic therapy was contraindicated or had 
failed.
1.10 Methods
1.10.1 Study design
This will be a retrospective, descriptive and analytical study where the files of patients with
confirmed PE on CTPA within the period of 1 January 2013 to 31 December 2013.
1.10.2 Study population
All patients that had CTPAs requested at the Department of Radiology at CHBAH and had
a PE confirmed between 1 January 2013 -  31 December 2013 will be included -  498
patients have been identified.
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1.11 Data analysis
After collection of files of patients with confirmed PE within the period of one year, the 
PE will be classified into high risk and non-high risk PE and their management noted in 
terms of whether thrombolysis or anti-coagulation was used. If thrombolysis was not used 
in patients with high risk PE due to the presence of contraindications, these will also be 
noted (figure 1). The other features being analysed will be the HIV status, the level of d- 
dimers, the Wells score and revised Geneva score, any complications of thrombolysis in 
the setting of high risk PE and the type of complication, whether surgical or percutaneous 
embolectomy was used in patients where thrombolysis was contra-indicated in the setting 
of high risk PE. Categorical variables were compared using the chi square test. The 
students t test was used to compare continuous and normally distributed variables and the 
McNemar’s test was used where variables were not variably distributed. An additional 
analysis was also included which was not part of the initial objectives and this analysed the 
various predictors of mortality in patients with confirmed PE by means of univariate and 
multiple logistic regression analysis(Figure land Table 4,5).
1.12 Ethics
Ethical approval will be sought from the Human Research Ethics Committee of the 
University of the Witwatersrand and the Department of Internal Medicine Protocol 
Assessment Committee. No identifiable patient information will be used in this research 
project and their anonymity and confidentiality will be maintained. Only the primary 
researcher will have access to the data set and permission to conduct the research will be 
sought from the CEO of CHBAH.
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1.13 Timing
v if :v 'l i  I
1.14 Funding
Photocopying and printing are the only expenses that will be incurred to carry out this 
research project and these will be covered by myself.
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Background:
Pulmonary embolism (PE) is the most common cause of preventable deaths in 
hospitalized patients.
Objectives:
To determine the incidence and associated features of PE at Chris Hani Baragwanath 
Academic Hospital (CHBAH) over one year.
Methods:
A retrospective study was performed of patients with confirmed PE on computed 
tomography of the pulmonary arteries (CTPA) during 2013 and by means of a formatted 
data collection sheet, demographical and other relevant data was collected.
Results: There were 498 CTPAs requested at CHBAH in 2013 and 147 (30%) of these 
confirmed the presence of PE. The mean age of the patients with PE was 47 ± 15.49 
years. At least 41 % of the patients with PE were HIV positive. The Wells and revised 
Geneva score were comparable in predicting clinical probability of PE. Only 15% of the 
patients with high risk PE were thrombolysed, with no documented complications.
Conclusion:
PE is a common and serious medical condition in CHBAH and its management needs 
further optimization to improve clinical outcomes.
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Introduction
Pulmonary embolism (PE) occurs when there is an occlusion to the blood supply to a 
portion of the lung caused by a blood clot which embolises to lungs from peripheral veins. 
This prevents oxygenated blood from reaching the brain and other vital organs.1
The European Society of Cardiology (ESC) guidelines have proposed classifying PE 
according to the estimated risk of early death (inpatient or 30-day mortality) directly related 
to the PE. With this classification a high risk PE is characterized by haemodynamic 
instability, which according to the ESC guidelines is defined as a systolic blood pressure 
(SBP) of less than 90 or a drop in blood pressure of s 40mmHg for more than 15 minutes 
that cannot be explained by another cause such as new onset arrhythmia, hypovolaemia 
or sepsis.2,3 High risk PE may or may not be accompanied by right ventricular (RV) 
dysfunction and myocardial injury, it carries a short term mortality of 15%.2
Non-high risk PE is divided into moderate risk and low risk PE. Moderate risk PE is 
diagnosed when there is RV dysfunction and/or myocardial injury in a haemodynamically 
stable patient and low risk PE is when there is neither RV dysfunction nor myocardial 
injury.2 In the more recent ESC guidelines from 2014 the subdivision of non-high risk PE 
into moderate and low risk PE is not mentioned, most likely to not complicate the clinically 
relevant distinction between high and not high risk PE.3
The annual incidence of PE in South Africa (SA) is unknown but in the United States of 
America (USA) it is estimated at 600 000 cases. 2 The prevalence amongst hospitalized 
patients over a 21-year period (1979 -1999) in the USA was 0.4%.2 4 Mortality figures for 
acute PE range from 7 — 11 % .2 In Sweden, an analysis of 2356 autopsies performed in 
1987, showed venous thromboembolism in 595 (25%) and PE in 431 (18.3%). In 308 of
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the autopsies, PE was considered to have caused or contributed to the deaths.2 5 PE is 
regarded as the most common cause of preventable deaths in hospitalized patients and 
the annual healthcare cost attributable to treatment of venous thromboembolism (VTE) is 
estimated to be more than 1.5 billion US dollars.6 These studies leave no doubt that PE is 
a prevalent condition, and is associated with a high, yet preventable mortality rate.
No similar studies focusing on the features and management of PE have been conducted 
in SA. The aim of this study was to assess the number of high risk and non high risk PE 
confirmed on computed tomography of the pulmonary arteries (CTPA) at Chris Hani 
Baragwanath Academic Hospital (CHBAH) over the period of one year and assess the 
significance of the various characteristics and the management of patients with confirmed 
PE.
Methods
Study population and sample
This was a retrospective study where all CTPA reports performed during the period of 1 
January 2013 to 31 December 2013 were reviewed. The files of patients with confirmed 
PE on CTPA were pulled and further data was collected. The data analysed included 
demographics, admission ward, HIV status, CD4 count, anti-retroviral therapy (ART), D- 
dimer levels; mortality, the Wells and revised Geneva scores. The management of PE and 
possible complications thereof were also analysed. Other details collected included co­
morbidities, Doppler ultrasounds and echocardiograms reports if available. There were no 
exclusion criteria.
Definitions
High risk PE was characterized by haemodynamic instability, which according to the ESC 
guidelines was defined as a systolic blood pressure of less than 90 or a drop in blood
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pressure of > 40mmHg for more than 15 minutes that could not be explained by another 
cause such as new-onset arrhythmia, hypovolaemia or sepsis.2,3
Non-high risk PE was further classified into moderate risk and low risk PE. Moderate risk 
PE was diagnosed when there was RV dysfunction and/or myocardial injury in a 
haemodynamically stable patient and low risk PE was when there was neither RV 
dysfunction nor myocardial injury.2
Statistical analysis
All the CTPA reports from the year 2013 were analysed and the ones with a confirmed PE 
were identified. A study number was allocated to each participant with a confirmed PE. A 
separate data sheet correlated names with a study number. All the captured data was 
recorded in Microsoft Excel sheets. The chi square test was used to compare categorical 
variables. For continuous variables the students t test was used when variables were 
normally distributed and where the variables were not variably distributed the McNemar’s 
test was used. Univariate and multiple logistic regression analysis was used to determine 
predictors of in-hospital mortality for patients with PE.
Results
Overall incidence of PE
From the period of 1 January 2013 to 31 December 2013 there were 498 CTPA requests 
to exclude PEs at CHBAH, of these 147 CTPAs confirmed the diagnosis. The majority of 
the CTPAs were requested from the medical wards (79%) and 29% showed PE. 
Demographics
A substantial proportion (78%) of the patients with PE comprised of females. The mean 
age of the patients was 47 ± 15.49 years. The mean age of patients who were
23
thrombolysed was 48.5 ± 14.6 years and of those not thrombolysed was 42.6 ±11.5 
(P=0.33). The study comprised of 137 black patients. (Table 3)
HIV, CD4 counts and ART
In this study 60 patients out of 147 (41%) with confirmed PE on CTPA were HIV positive. 
The HIV results of 37 patients were not available from either the files not being found or 
the test not being done. The CD4 counts of 45 HIV positive patients were found and over 
60% of these patients had a CD4 count < 200 cells/mm3. Amongst the HIV positive 
patients 24 were on ART, information was missing from 13 patients who were HIV positive 
regarding whether they were on ART or not.
Table 3: Demographics
Characteristics of the study sample
Value N(%) Missing value (N)
Characteristics
Patients with confirmed PE 147(29.5)
High risk PE 33(22.4)
Thrombolysed 6(18.2)
General characteristics (Mean ± SD)
Mean age (years) 46.82(15.2)
SBP (mmHg) 118.2(24.7)
DBP(mmHg) 73.9(15.5)
HR b.p.m 111.5(17.0)
Women 115(78.2)
Blacks 137(93.2)
HIV 60(40.8) 37
CD4 count < 200 cells/mm3 28(62.2) 15
ARVs 24 h 13
Comorbidities
fBMI 24 29
TB 13 39
Malignancy 7 39
DVT 16 53
COPD/smoker 6 39
N= Number; SBP systolic blood pressure in mmHg; DBP diastolic blood pressure in
mmHg; b.p.m beats per minute
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Serum D-dimer levels
There were 70 patients who did not have a D-dimer result either because the files could 
not be found or the test was not done. The average serum D-dimer level was 3.7mg/l ±3.3. 
The serum D-dimer results of four patients which were specified but were only noted as 
raised and therefore could not be used to calculate the average D-dimer levels. There was 
only one result that was negative amongst the patients with a confirmed PE.
Mortality
There were 28 deaths (24%) amongst patients diagnosed with a PE on CTPA, this is 
excluding 28 patients where this data was missing. Thirteen (46%) of the 28 deaths were 
patients with high risk PE and 2 were thrombolysed. Malignancies were confirmed in three 
of these patients and two had suspected malignancies. There were six patients who had 
TB and one patient had PJP. There were nine HIV positive patients, five had a high body 
mass index (BMI) as noted in the files but a specific value was not specified. Univariate 
and multivariate analysis for independent predictors of mortality was performed on 88 
patients where all the required data was available. The majority (79%) of the patients who 
died were female. On univariate logistic regression analysis, age in years after 40 was the 
only predictive factor of mortality with a p value=0.007 and an odds ratio of 1.04. Obesity, 
gender, thrombolysis and HIV were not found to be statistically significant in predicting 
mortality on univariate analysis. Age continued to be an independent predictor (odds ratio 
of 1.06 and p value=0.01) of mortality in a multivariate model when adjusted for other 
variables such as obesity, gender, HIV and thrombolysis. (Table 4)
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Table 4: Multivariate analysis of predictors of mortality
Mortality OddsRatio [95% Conf. Interval]
Obese 0.89 0.22 - 3.54
RVD 1.77 0.55 - 5.63
Age 1.06 1.01 - 1.12*
Gender 1.28 0.37-4.46
Thrombolysed 2.01 0.31 - 12.84
* P < 0.05
Wells and revised Geneva scores
According to the Wells score 31 (35%) patients with a confirmed PE on CTPA had a high 
probability, 54 (61%) had an intermediate probability, and 3(3%) had a low probability. 
Data regarding the Wells score was available from 88 of the 147 patients. Comparatively 
according to the revised Geneva score 31 (36%) had a high probability, 50 (58%) patients 
had an intermediate probability and 5 (6%) had a low probability of a PE. Data regarding 
the revised Geneva score was available from 86 of the 147 patients. This illustrates a 
close correlation between the two scores in this study. (Figure 1.)
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70%
high(P=0.78) intermediate(P=0.78) low(P=0.12)
* wells score * revised geneva score
Figure 1: Comparison between the Wells and revised Geneva scores 
Thrombolysis and embolectomy
There were 33 patients out of the 147 with confirmed PE (22.4%) who met the criteria for a 
high-risk PE according to the definition outlined by the ESC guidelines. Of these, five 
(15%) patients received thrombolysis. One patient did not meet the criteria of a high-risk 
PE but was thrombolysed based on echocardiographic findings of RV dysfunction. There 
was a 39% mortality amongst patients with a high-risk PE (table 5). There were no 
documented complications of thrombolysis. None of the patients had a surgical or 
percutaneous embolectomy but one had an IVC filter implanted and was being considered 
for a surgical embolectomy which was still to be done upon discharge.
Table 5: Incidence of thrombolysis of high risk PE at CHBAH in 2013
Number of CTPAs 
requested in 2013
Number of 
confirmed PE on 
CTPA
Number of high 
risk PE
Number of high 
risk PE 
thrombolysed
498 147(29.5%) 33 (22.4%) 5 (15.2%)
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Discussion
Incidence and demographics
A study conducted in New Jersey between 1998 -2000, found the incidence of PE to be 
higher in black Americans compared to white patients. This study yielded similar results 
but it’s difficult to comment on the increased incidence in blacks compared to whites as the 
majority of the patient population at CHBH were black.7
In a comparable study conducted in Sweden in 2006, 343 patients from a total of 517 with 
potential VTE, were found to have a confirmed VTE. Of the 343, 161 had a PE (31.1%). 
The mean age of diagnosis was 67.6 for men and 72.5 for women. The commonest risk 
factors were recent hospital admission and malignancy. The incidence in this study was 
similar but the mean age of diagnosis was much lower, which is not surprising as the 
majority of patients admitted at CHBAH have HIV associated conditions and are much 
younger.8
Inter-departmental incidence analysis
In a study that looked at the trends of outcomes for PE in the US it was found that 28.8% 
of the patients were classified as surgical and 71% as non-surgical.6 We found that 78% of 
the patients in this study were non-surgical, possibly due to increased vigilance amongst 
physicians of the risk of PE but this is worrisome due to the obvious risk factors for PE in 
surgical wards.
HIV infection
HIV infection is an independent risk factor for VTE which explains that 41% of patients with 
PE in this study were HIV positive. There is a higher incidence of VTE in HIV patients with 
lower CD4 counts which is related to an increasing hypercoagulable state which occurs
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with progressive immune suppression associated with HIV disease progression.91011 The 
bulk of the HIV infected patients diagnosed with PE in this study had a CD4 count less 
than 200cells/mm3 which is known to cause a higher risk of thrombosis compared to 
patients with higher CD4 counts.
Advancing age is a risk factor for thrombosis in the general population in the developed 
world but the mean age of HIV infected patients at the time of VTE is 40 years which is 20 
years less than their non-infected counterparts.11 This finding also held true in this study 
but the difference was more exaggerated with the mean age of patients with HIV infection 
and a confirmed PE was 24 years.
Some studies have shown that the introduction of HAART has increased the incidence of 
VTE in HIV positive patients, protease inhibitors (Pis) in particular have been implicated, at 
least 40% of the HIV positive patients in this study were on HAART, although the exact 
regimen was not documented.1011 As Pis form part of second line therapy in HIV patients, 
the increased risk for PE in these patients might also be partly due to the poor general 
state of these patients with lower CD4 counts and possibly other opportunistic co­
morbidities.
Thrombolysis and embolectomy
Only 15% of patients with high risk PE were thrombolysed in this study, one patient with an 
intermediate risk PE was thrombolysed because of features of RV strain on 
echocardiogram. One patient was not thrombolysed due to recent spinal surgery, another 
was a 19-year old patient with primary anti-phospholipid syndrome who was out of the 
window period for thrombolysis She had an IVC filter inserted and was planned for a 
surgical embolectomy but was not yet done upon discharge. There were no documented
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complications of thrombolysis noted in any of these cases. The mortality rate was 39% 
amongst high risk PE patients. The average age of patients in the thrombolysis versus the 
non-thrombolysis group was very similar ranging from 42 to 43 years, therefore age clearly 
did not play much of a role in the decision regarding management. According to a study 
comparing mortality rates between patients with high risk PE who received and did not 
receive thrombolytic therapy, it was found that the fatality rates were lower in the 
thrombolysed group.12 It was also found that the addition of a vena cava filter and 
thrombolysis further reduced the fatality rate.12 This emphasizes the underutilization of 
thrombolysis at CHBAH, the reasons for this may be a reluctance on the part of the 
treating doctor to thrombolyse due to its potential complications and the need for close 
monitoring during and post thrombolysis or possibly a lack of awareness , regarding its 
short and long term benefits and the window period of 14 days since beginning of 
symptoms where it can still be utilized. IVC filters also are underutilized and may have 
added benefit on top of thrombolysis in improving clinical outcomes of patients with high 
risk PE.12 Surgical and percutaneous embolectomy is evidently not considered often 
enough as a treatment modality in patients where thrombolysis might be contraindicated.
The Wells and revised Geneva scores
The Wells and revised Geneva score both have similar accuracy in predicting the 
likelihood of PE in the high, intermediate and low category.2 These scores were not always 
documented in the files of these patients and were calculated based on information in the 
file where they were otherwise missing. This study showed strong similarities between the 
two scoring systems and both placed the majority of patients in the intermediate category. 
This can be explained partly in the context of the population at CHBAH where the mean 
population is much lower than 65 which is a component of the Wells score. Only 16 
patients had DVTs confirmed on Doppler ultrasound, three did not show a DVT and for the
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remaining patients either the data could not be found or the ultrasounds were not done. 
Most records made a comment on the suspicion of a DVT and the possibility of proximal 
DVTs cannot be excluded.
In this study, seven patients had a confirmed malignancy, one had a low grade squamous 
intra-epithelial lesion (LGSIL) and 2 had suspected malignancies. Of the confirmed 
malignancies 4 were lymphomas and the remaining three were Kaposi’s sarcoma, breast 
carcinoma and bronchial carcinoma. This is in keeping with studies which have shown that 
haematological, lung, gastro-intestinal, pancreatic and brain malignancies carry higher risk 
of VTE.3 A large proportion of the patients were HIV positive and had active TB which are 
both well known as a risk factors for VTE but are not included in either one of these 
scores, further study using a control group would prove valuable to perhaps decide on the 
inclusion of these risk factors in these scores in areas where they are endemic.
A recently published study from the Western Cape investigated the increase in yield of 
positive CTPAs when an electronic clinical decision support (CDS) system, which 
comprised of the modified Wells score and the D-dimer test result, was implemented. The 
percentage of positive CTPAs increased by 14.3% after using this system.13 In our study 
the incidence of positive CTPAs was almost 30% despite the lack of a strict protocol to 
obtain a CTPA.
Although the importance of clinical probability is undeniable in risk assessment for PE, the 
more popular original Well’s score has a subjective criterion “alterative diagnosis less likely 
than PE” which carries a score of 3 and together with a non-specific criteria of a heart rate 
more than 100 beats per minute which carries 1.5 points and already puts the probability 
of PE as “likely”. There are numerous clinical confounders resembling PE in the South
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African population which in turn also increase their risk for a PE. This in turn makes the 
overutilization of CTPA far less harmful than its underutilization considering the associated 
morbidity and mortality of missing the diagnosis of a PE.
The importance of clinical presentation cannot be overemphasized and as risk stratification 
scores are merely tools to improve the specificity of a certain diagnosis, the clinical 
condition of the patient is paramount in deciding on further investigations. Although there 
are many confounders with similar presentation to a PE, especially in the South African 
setting, it must be born in mind that the South African population is the very population at 
highest risk for PE with the HIV pandemic and the various associated prothrombotic 
conditions.
D-dimer levels
The sensitivity of D-dimer levels is well acknowledged and this study did not dispute this, 
with all the D-dimer levels in patient with confirmed PE being raised except for one. This 
was a 52 year old male patient with multiple myeloma for more than 20 years and on 
thalidomide since 2010. He also had a previous history of right leg deep vein thrombosis 
(DVT) in 2007 for which he received warfarin for six month. He had presented on the 
current admission with a DVT in the left leg confirmed on Doppler ultrasound and his 
CTPA showed chronic PTED. This might be attributed to the time from onset of symptoms 
to presentation which is known to significantly decrease the D-dimer levels, but more 
importantly this case highlights the importance of clinical suspicion as being the main 
driver of aggressive investigation for a possible PE regardless of the D-dimer result as the 
Wells and revised Geneva score both put this patient in a high-risk category for a PE.
Predictors of mortality
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In this study the only variable found to be a statistically significant predictor of mortality 
was age. This is not surprising due to the many co-morbidities that are present in the older 
population and this finding was shared in a study which looked at the predictors of in- 
hospital and long term mortality in patients with acute PE and found older age to be a 
significant factor with a p value=0.031.14
A recently published study from the Western Cape investigated the increase in yield of 
positive CTPAs when an electronic clinical decision support (CDS) system, which 
comprised of the modified Wells score and the D-dimer test result, was implemented. The 
percentage of positive CTPAs increased by 14.3% after using this system.13 In this study 
the incidence of positive CTPAs was almost 30% despite the lack of a strict protocol to 
obtain a CTPA.
Limitations
This was a retrospective study and the data collection was reliant on the manual record 
keeping system at CHBAH, therefore not all the relevant information were available for all 
cases. This compromised the accuracy of some of the objectives of the study especially 
the D- dimer levels, but from the proportion of the other results the findings most likely 
would have been exaggerated if all the data were available.
Conclusion
PE occurs frequently at CHBAH and is more common in middle aged, HIV positive 
females. The majority of the CTPAs are requested from the medical wards. The Wells and 
the revised Geneva score are comparable in predicting the likelihood of PE. Thrombolysis 
is gravely underutilized where it is clinically indicated in high risk PE. There is a significant 
mortality in patients diagnosed with PE and age was found to be the only significant
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predictor of mortality. Surgical and percutaneous embolectomy are rarely considered as 
treatment modalities in patients who have contraindications to thrombolysis and IVC filters 
are also infrequently utilized. No complications of thrombolysis were reported.
The way forward
The purpose of this study was to statistically define the impact of the diagnosis and 
management of PE at CHBAH so that improvement can be made in areas where problems 
were identified. Thrombolysis is grossly underutilized and this needs to change to optimize 
the short and long term outcomes of patients with PE. A greater use must be made of 
surgical and percutaneous embolectomy where thrombolysis is contraindicated and close 
collaboration between medical and surgical doctors is needed to implement this.
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Chapter 3: APPENDICES 
3.1 Data collection form
Case
no Risk Thrombolysis Anticoagulated RVD
CD4
count
D-
dimer
High Nothigh Yes No Yes No Positive Negative
Wells score Revised Geneva score Mortality
Yes No
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